After signing a groundbreaking deal with cosmetics company L’Oreal for the development of 3D printed skin for cosmetics testing, Organovo continues to make partners in powerful places. On April 17, the bioprinting company filed a Form 8-K with the SEC stating a multi-year partnership with pharmaceutical giant Merck & Co. that involves both the use of the company’s exVive3D liver tissues and the use of their NovoGen Bioprinting system for developing medicines. The exact wording of the document is as follows:
On April 17, 2015, Organovo (NYSE: ONVO) entered into a multi-year research collaboration agreement with Merck Sharp & Dohme Corp. (NYSE: MRK). The Agreement will give Merck access to Organovo’s commercial exVive3DTM Human Liver Tissue service, and will also involve a collaboration to develop multiple custom tissue models utilizing the Company’s proprietary NovoGen Bioprinting PlatformTM, for use in drug development.
